A real-world study of EGFR tyrosine kinase inhibitors (TKIs) for advanced Non-small cell lung cancer patients with x19dels
Latest Information Update: 10 Jun 2020
At a glance
- Drugs Afatinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology